Ostarine may be the closest SARM to becoming permitted in medicine and it is at this time in stage II clinical trials. Like SARMs on the whole, MK-2866 targets androgen receptors on the selective basis and avoids creating the types of destructive side effects associated with substances like testosterone, human https://virgilp877hxm5.wssblogs.com/profile